Protagonist Therapeutics
Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update
MIMRYLO™ (rusfertide) Approved by FDA for the Treatment of Erythrocytosis in Adults with Polycythemia Vera; Approval Triggered $275 Million in…